Key result
Among 7,917 STEMI patients in Eastern Europe, a quarter did not receive reperfusion therapy, resulting in 30-day mortality rates double those of fibrinolysis and treble those of primary PCI.
Why the study?
Does reperfusion therapy reduce 30-day mortality in STEMI patients in Eastern Europe?
Does reperfusion therapy reduce 30-day mortality in STEMI patients in Eastern Europe?
Answers are grounded in this paper and cite their sources.
Despite clear guidelines, a significant proportion of STEMI patients in Eastern Europe do not receive reperfusion therapy, resulting in markedly higher 30-day mortality.
This editorial refers to “Reperfusion therapy for ST-elevation acute myocardial infarction in Eastern Europe: the ISACS-TC registry”, by E. Cenko et al ., on page 45. Reperfusion therapy, either by intravenous fibrinolysis or percutaneous coronary intervention (PCI), is the cornerstone of the management of ST-elevation myocardial infarction (STEMI). 1 Randomized data have demonstrated its effectiveness in reducing mortality and morbidity, and the benefit is all the greater when it is performed early. 2 , 3 As such, coronary reperfusion for STEMI performed within a short time frame is recommended and its timely implementation used as an indicator of quality of care. 4 The estimated times to reperfusion also contribute largely to the choice of reperfusion strategy, with primary PCI being the technique of choice except if it is estimated that it cannot be performed within 120 min. 1 Despite this, many patients fail to receive guideline-indicated therapies for STEMI and the proportion who do varies geographically. 5 Addressing the variation in STEMI care will help reduce the substantial difference in mortality rates from cardiovascular disease between European countries. 6 The choice of reperfusion strategy and the ability to achieve timely reperfusion are, however, often constrained by the availability and functionality of specialist clinical services. 7 Whilst STEMI networks of care are associated with higher attainment of measures of processes (such as reperfusion times) and improved clinical outcomes (such as death from all causes at 30 days), they require substantial financial investment and coordinated action from a range of healthcare disciplines who encounter the patient with STEMI along their journey of care. 7 That is, despite robust evidence for the benefits of primary PCI for the emergency management of STEMI, its diffusion across healthcare systems is often protracted. 8 This is important when delayed implementation of new cardiovascular health technologies is associated with potentially avoidable deaths. 9 Across Eastern Europe, where there are economies in transition, the use and timeliness of reperfusion therapy for STEMI are suboptimal. 10 Cenko et al . used the prospective International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) registry to show that among 7917 STEMI eligible for reperfusion therapy across 57 hospital in Eastern Europe between 2010 and 2015, a quarter did not receive either fibrinolysis or primary PCI. 11 Even though other research has suggested that an equally high proportion of STEMI do not receive reperfusion therapy, 5 this is one of the first reports among the transitional countries of Europe. Their research clearly highlights the considerable prospect for improvements in cardiovascular health across Eastern Europe whereby mortality rates at 30 days among the non-reperfused were double those who received fibrinolysis and treble those who received primary PCI. Added to this is the fact that the rates of primary PCI were much lower than those for fibrinolysis—thereby diluting our expected gains from STEMI reperfusion. Cenko et al . found that the independent predictors of not attempting reperfusion were time of hospitalization over 12 h, female sex, increasing age, prior myocardial infarction, cerebrovascular disease, chronic kidney disease, and a Killip class of I. 11 Whilst these factors are usually reported as non-modifiable, this is only true at the level of the patient. That is, even though our past medical history is fixed, at the level of the healthcare system such factors are amenable to quality improvement. Furthermore, such a ‘systems change’ is realizable as evidenced in Sweden, 9 through creating ‘intelligent’ organizations that are operationally routinised 12 but have the ability to react to their specific evidence–practice gaps by identifying and treating those patients at the greatest risk of not receiving guideline-indicated care. In Western Europe, there is also good evidence for imperfect care for the management of STEMI. The UK national heart attack registry, Myocardial Ischaemia National Audit Project (MINAP), has shown that although there have been huge improvements in quality of care and clinical outcomes for STEMI, 13–15 when the individual elements of the pathway of care are studied in sequence, many patients were found to have missed opportunities to receive guideline recommended treatments. 16 Moreover, inequalities in the management and outcomes of STEMI are apparent both between and within high performing countries. 17 Compared with Eastern Europe, Western Europe appears further ahead in its achievement of a more comprehensive STEMI programme, yet there are readily apparent defects in care which should not be overlooked. Notably, a similarity between the two geographies is that the identification of areas for improvement would not be possible except for the systematic collection of clinical data. 18 , 19 Changes to the delivery of cardiovascular medicine over the past few decades have been mirrored by an increasing emphasis on the measurement and reporting of quality of care and outcomes, and the structured collection of data through clinical registries. Clinical registries now play a critical international role in STEMI quality accounts and will be central to the development of performance measures for healthcare improvement. 20 For the United Kingdom, organizational routinization for STEMI has been achieved and has been associated with a significant reduction in death. However, the 8-year implementation phase across the 247 hospitals and around 40 000 STEMI per year is a reflection of the task which lies ahead for Eastern Europe. 8 The ISACS-TC registry is a welcome international resource which will, no doubt, facilitate through research and its reporting of the delivery of STEMI care a reduction in the burden of cardiovascular disease across Eastern Europe.
No takes yet. Share an insight, caveat, or question.
Chris P Gale (2016) conducted an editorial in ST-elevation myocardial infarction (STEMI) (n=7,917). Reperfusion therapy (fibrinolysis or primary PCI) vs. No reperfusion therapy was evaluated on Mortality at 30 days. Among 7,917 STEMI patients in Eastern Europe, a quarter did not receive reperfusion therapy, resulting in 30-day mortality rates double those of fibrinolysis and treble those of primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: